Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 24704000)

1.

Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.

Tulsyan S, Chaturvedi P, Singh AK, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B.

Gene. 2014 Jun 10;543(1):69-75. doi: 10.1016/j.gene.2014.04.004. Epub 2014 Apr 2.

PMID:
24704000
2.

Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach.

Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B.

Mol Diagn Ther. 2013 Dec;17(6):371-9. doi: 10.1007/s40291-013-0045-4.

PMID:
23812950
3.

Influence of ABCB1 genetic variants in breast cancer treatment outcomes.

Chaturvedi P, Tulsyan S, Agarwal G, Lal P, Agarwal S, Mittal RD, Mittal B.

Cancer Epidemiol. 2013 Oct;37(5):754-61. doi: 10.1016/j.canep.2013.04.012. Epub 2013 May 23.

PMID:
23707158
4.

Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.

Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY, Hou MF.

Clin Chim Acta. 2009 Jun 27;404(2):160-5. doi: 10.1016/j.cca.2009.03.038. Epub 2009 Mar 28.

PMID:
19332043
5.

Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.

Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, Ferlini A.

Breast Cancer Res Treat. 2010 Nov;124(2):593-8. doi: 10.1007/s10549-010-1034-5. Epub 2010 Jul 15.

PMID:
20632082
6.

Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.

Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC.

Ann Oncol. 2009 Feb;20(2):272-7. doi: 10.1093/annonc/mdn624. Epub 2008 Oct 3.

7.

Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.

Tulsyan S, Agarwal G, Lal P, Mittal B.

Clin Chim Acta. 2014 Jul 1;434:21-8. doi: 10.1016/j.cca.2014.04.009. Epub 2014 Apr 24.

PMID:
24768782
8.

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV.

Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23.

9.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000. Review.

PMID:
20170205
10.

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.

Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH.

Clin Pharmacol Ther. 2005 Nov;78(5):551-8. Epub 2005 Sep 26.

11.

ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.

Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M.

Int J Colorectal Dis. 2009 Aug;24(8):895-905. doi: 10.1007/s00384-009-0724-0. Epub 2009 May 5.

PMID:
19415305
12.

ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY.

Cancer Sci. 2015 Jan;106(1):86-93. doi: 10.1111/cas.12560. Epub 2014 Dec 8.

PMID:
25410489
13.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Apr;49(4):207-21. doi: 10.2165/11317550-000000000-00000. Review.

PMID:
20214406
14.

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.

Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD.

Clin Cancer Res. 2008 Jul 15;14(14):4543-9. doi: 10.1158/1078-0432.CCR-07-4230.

15.

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.

Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, Kang SB.

Gynecol Oncol. 2009 May;113(2):264-9. doi: 10.1016/j.ygyno.2009.01.002. Epub 2009 Feb 8.

PMID:
19203783
16.

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.

Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS, Ahn SH.

Cancer Chemother Pharmacol. 2012 May;69(5):1221-7. doi: 10.1007/s00280-011-1816-4. Epub 2012 Jan 20.

PMID:
22271208
17.
18.

Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.

Choi JR, Kim JO, Kang DR, Shin JY, Zhang XH, Oh JE, Park JY, Kim KA, Kang JH.

Cancer Res Treat. 2015 Jul;47(3):509-17. doi: 10.4143/crt.2014.012. Epub 2014 Dec 16.

19.

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS.

Cancer. 2007 Jul 1;110(1):138-47. Erratum in: Cancer. 2010 Aug 1;116(15):3749.

20.

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC.

Breast Cancer Res Treat. 2012 Jul;134(1):401-10. doi: 10.1007/s10549-012-2054-0. Epub 2012 Apr 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk